Critical Limb Ischemia - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Critical Limb Ischemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H2 2015', provides an overview of the Critical Limb Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Critical Limb Ischemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Critical Limb Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Critical Limb Ischemia Overview 10
Therapeutics Development 11
Pipeline Products for Critical Limb Ischemia - Overview 11
Pipeline Products for Critical Limb Ischemia - Comparative Analysis 12
Critical Limb Ischemia - Therapeutics under Development by Companies 13
Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 15
Critical Limb Ischemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Critical Limb Ischemia - Products under Development by Companies 19
Critical Limb Ischemia - Products under Investigation by Universities/Institutes 21
Critical Limb Ischemia - Companies Involved in Therapeutics Development 22
AnGes MG, Inc. 22
Apceth GmbH & Co. KG 23
Athersys, Inc. 24
Caladrius Biosciences, Inc. 25
Cynata Therapeutics Limited 26
DNAVEC Corporation 27
Hemostemix Ltd 28
IntelliCell BioSciences Inc. 29
Juventas Therapeutics, Inc. 30
Kasiak Research Private Limited 31
Multi Gene Vascular Systems Ltd 32
Pharmicell Co., Ltd. 33
Pluristem Therapeutics Inc. 34
ReNeuron Group Plc 35
Stempeutics Research Private Limited 36
Targazyme, Inc. 37
TikoMed AB 38
U.S. Stem Cell, Inc. 39
Vericel Corporation 40
ViroMed Co., Ltd. 41
Critical Limb Ischemia - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
ACP-01 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AdipoCell - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Alecmestencel-T - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ASCT-01 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Autologous Vascular Cells Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
beperminogene perplasmid - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cell Therapy for Critical Limb Ischemia - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cellgram for Severe Lower Limb Ischemia - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CLBS-12 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DVC1-0101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ixmyelocel-T - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JVS-100 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MultiGeneAngio - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MultiStem - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PLX-PAD - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Recombinant Protein for Critical Limb Ischemia - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Refacell-CLI - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Rejuveinix - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ReN-009 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Stempeucel - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
TM-700 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TZ-101 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
VM-202 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Critical Limb Ischemia - Recent Pipeline Updates 101
Critical Limb Ischemia - Dormant Projects 129
Critical Limb Ischemia - Discontinued Products 130
Critical Limb Ischemia - Product Development Milestones 131
Featured News & Press Releases 131
Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa 131
Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan 131
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications 132
Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia 132
Aug 12, 2015: Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials 133
Aug 10, 2015: Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States 133
Jul 27, 2015: Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia 133
Jun 25, 2015: Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia 134
Jun 18, 2015: Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company's ACP-01 Formulation to Treat Critical Limb Ischemia 134
Jun 08, 2015: Stempeutics receives Japan process patent for its novel stem cell drug, Stempeucel 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List of Tables

Number of Products under Development for Critical Limb Ischemia, H2 2015 11
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H2 2015 22
Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2015 23
Critical Limb Ischemia - Pipeline by Athersys, Inc., H2 2015 24
Critical Limb Ischemia - Pipeline by Caladrius Biosciences, Inc. , H2 2015 25
Critical Limb Ischemia - Pipeline by Cynata Therapeutics Limited, H2 2015 26
Critical Limb Ischemia - Pipeline by DNAVEC Corporation, H2 2015 27
Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H2 2015 28
Critical Limb Ischemia - Pipeline by IntelliCell BioSciences Inc., H2 2015 29
Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2015 30
Critical Limb Ischemia - Pipeline by Kasiak Research Private Limited, H2 2015 31
Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015 32
Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2015 33
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2015 34
Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H2 2015 35
Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2015 36
Critical Limb Ischemia - Pipeline by Targazyme, Inc., H2 2015 37
Critical Limb Ischemia - Pipeline by TikoMed AB, H2 2015 38
Critical Limb Ischemia - Pipeline by U.S. Stem Cell, Inc., H2 2015 39
Critical Limb Ischemia - Pipeline by Vericel Corporation, H2 2015 40
Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Stage and Target, H2 2015 44
Number of Products by Stage and Mechanism of Action, H2 2015 46
Number of Products by Stage and Route of Administration, H2 2015 48
Number of Products by Stage and Molecule Type, H2 2015 50
Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H2 2015 101
Critical Limb Ischemia - Dormant Projects, H2 2015 129
Critical Limb Ischemia - Discontinued Products, H2 2015 130